About Biogen (NASDAQ:BIIB)
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:BIIB
- CUSIP: 09062X10
- Web: www.biogen.com
- Market Cap: $71.48 billion
- Outstanding Shares: 211,431,000
- 50 Day Moving Avg: $324.65
- 200 Day Moving Avg: $285.82
- 52 Week Range: $244.28 - $348.84
Sales & Book Value:
- Trailing P/E Ratio: 22.19
- Foreward P/E Ratio: 14.50
- P/E Growth: 2.39
- Annual Revenue: $11.72 billion
- Price / Sales: 6.10
- Book Value: $54.79 per share
- Price / Book: 6.17
- EBITDA: $6.42 billion
- Net Margins: 28.10%
- Return on Equity: 37.42%
- Return on Assets: 20.12%
- Debt-to-Equity Ratio: 0.51%
- Current Ratio: 2.10%
- Quick Ratio: 1.83%
- Average Volume: 1.28 million shs.
- Beta: 0.77
- Short Ratio: 2.28
Frequently Asked Questions for Biogen (NASDAQ:BIIB)
What is Biogen's stock symbol?
Biogen trades on the NASDAQ under the ticker symbol "BIIB."
How were Biogen's earnings last quarter?
Biogen Inc. (NASDAQ:BIIB) released its quarterly earnings results on Tuesday, July, 25th. The company reported $5.04 EPS for the quarter, beating the Zacks' consensus estimate of $4.36 by $0.68. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. Biogen had a net margin of 28.10% and a return on equity of 37.42%. The company's revenue for the quarter was up 6.4% compared to the same quarter last year. During the same period in the previous year, the business earned $5.21 earnings per share. View Biogen's Earnings History.
When will Biogen make its next earnings announcement?
What guidance has Biogen issued on next quarter's earnings?
Biogen updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share (EPS) guidance of $20.80-21.40 for the period, compared to the Thomson Reuters consensus estimate of $20.37. The company issued revenue guidance of $11.5-11.8 billion, compared to the consensus revenue estimate of $11.40 billion.
Where is Biogen's stock going? Where will Biogen's stock price be in 2017?
25 analysts have issued twelve-month target prices for Biogen's shares. Their forecasts range from $271.00 to $442.00. On average, they anticipate Biogen's stock price to reach $342.83 in the next year. View Analyst Ratings for Biogen.
What are analysts saying about Biogen stock?
Here are some recent quotes from research analysts about Biogen stock:
- 1. Stifel Nicolaus analysts commented, "gigantic" aducanumab phase 3 trial, which started in 2015 and was 50 percent enrolled in the second quarter of 2017, Shrader commented in his upgrade note. This should be seen as a "no news is good news" scenario as the Data and Safety Monitoring Board has likely seen a lot of data and hasn't reported anything negative.Second, Biogen's partner Eisai is set to report an interim outlook at its plaque-busting mAb that targets the form of Ab plaque thought to lead to neuronal destruction, the analyst continued. The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen's often ignored stroke programs address a very large market. Of particular note, the company's Tysabri stoke program uncovered the "same cognitive and energy benefits in stroke patients that are routinely reported in MS patients" and turning this effect into a clinical endpoint that would be acceptable for the U.S. Food and Drug Administration is the likely next step.Finally, Ocrelizumab as part of the company's base business is "meh not mud," the analyst added. The therapy remains a drug with "remarkable anti inflammatory properties," but a commercial rollout will likely be "measured." (10/17/2017)
- 2. Mizuho analysts commented, "We looked through early Spinraza data to draw as close to apples to apples comparison as possible. Here is a chart we found (from an old BIIB deck), which shows Spinraza increases SMN protein by ~2.7x." (10/2/2017)
- 3. Cantor Fitzgerald analysts commented, "A German patient treated for three years with Tysabri and then with a single dose of Ocrevus developed PML." (5/25/2017)
- 4. Cowen and Company analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)
- 5. Instinet analysts commented, "We are initiating on BIIB with a Buy rating and $345 target price. We recommend owning BIIB shares over the next 12 months given limited 2017 downside to revenue forecasts and potential Spinraza launch upside. We estimate that a successful Spinraza launch will drive above-consensus revenues of $11.6bn in 2017 and $12.2bn in 2018, despite flat MS-franchise growth that may be impacted by emerging competition (Ocrevus). We anticipate this return to growth will drive modest revenue multiple expansion and strong GAAP EPS growth - to $19.41 in 2017 and $21.56 in 2018, yielding upside to our $345 target price." (3/1/2017)
Who are some of Biogen's key competitors?
Some companies that are related to Biogen include Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Abcam Plc (ABC), Anika Therapeutics (ANIK), Myovant Sciences Ltd (MYOV), Syros Pharmaceuticals (SYRS), Sinovac Biotech (SVA), ChemoCentryx (CCXI), Syndax Pharmaceuticals (SNDX), Strongbridge Biopharma PLC (SBBP), Mirna Therapeutics (SYBX), Mereo BioPharma Group PLC (MPH), Fortress Biotech (FBIO), Kamada (KMDA), Peregrine Pharmaceuticals (PPHM), Kadmon Holdings (KDMN), Vericel Corp (VCEL) and MediWound (MDWD).
Who are Biogen's key executives?
Biogen's management team includes the folowing people:
- Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board
- Michel Vounatsos, Chief Executive Officer, Director
- Gregory F. Covino, Interim Principal Financial Officer, Chief Accounting Officer, Vice President - Finance
- Ginger Gregory Ph.D., Chief Human Resource Officer, Executive Vice President
- Kenneth A. Di Pietro, Executive Vice President - Human Resources
- Susan H. Alexander Esq., Executive Vice President, Chief Legal Officer and Corporate Secretary
- Michael D. Ehlers M.D., Ph.D., Executive Vice President, Head - Research and Development
- Adriana Karaboutis, Executive Vice President - Technology , Business Solutions and Corporate Affairs
- Jean-Paul Kress M.D., Executive Vice President, President - International and Head of Global Therapeutic Operations
- Paul McKenzie Ph.D., Executive Vice President - Pharmaceutical Operations & Technology
Who owns Biogen stock?
Biogen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include APG Asset Management N.V. (0.22%), Assenagon Asset Management S.A. (0.19%), Rockefeller Financial Services Inc. (0.12%), Fisher Asset Management LLC (0.05%), State Treasurer State of Michigan (0.03%) and Oakbrook Investments LLC (0.03%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.
Who sold Biogen stock? Who is selling Biogen stock?
Biogen's stock was sold by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan, Bridges Investment Counsel Inc., Rockefeller Financial Services Inc., Fisher Asset Management LLC, Verde Servicos Internacionais S.A., Bridges Investment Management Inc. and Mutual of America Capital Management LLC. Company insiders that have sold Biogen stock in the last year include Alfred Sandrock, Brian S Posner, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Insider Buying and Selling for Biogen.
Who bought Biogen stock? Who is buying Biogen stock?
Biogen's stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Oakbrook Investments LLC, APG Asset Management N.V., Barometer Capital Management Inc., Shell Asset Management Co., Meeder Asset Management Inc., Eqis Capital Management Inc. and Montrusco Bolton Investments Inc.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.
How do I buy Biogen stock?
Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biogen's stock price today?
MarketBeat Community Rating for Biogen (NASDAQ BIIB)MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Biogen stock can currently be purchased for approximately $338.10.
Consensus Ratings for Biogen (NASDAQ:BIIB) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||9 Hold Ratings, 15 Buy Ratings, 1 Strong Buy Rating|
|Consensus Rating:||Buy (Score: 2.68)|
|Consensus Price Target: ||$342.83 (1.40% upside)|Consensus Price Target History for Biogen (NASDAQ:BIIB)
Analysts' Ratings History for Biogen (NASDAQ:BIIB)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/18/2017||Bank of America Corporation||Boost Price Target||Buy||$358.00 -> $365.00||N/A|
|10/17/2017||Morgan Stanley||Reiterated Rating||Buy||N/A|
|10/17/2017||Mizuho||Upgrade||Neutral -> Buy||$319.00 -> $400.00||N/A|
|10/17/2017||Stifel Nicolaus||Upgrade||Hold -> Buy||$300.00 -> $415.00||N/A|
|10/5/2017||Royal Bank Of Canada||Reiterated Rating||Hold||$315.00||N/A|
|9/21/2017||Raymond James Financial, Inc.||Downgrade||Strong-Buy -> Market Perform||$244.28 -> $319.00||Low|
|9/20/2017||SunTrust Banks, Inc.||Initiated Coverage||Buy -> Buy||$360.00||Low|
|9/13/2017||BMO Capital Markets||Boost Price Target||Market Perform||$328.00 -> $377.00||Low|
|8/25/2017||Robert W. Baird||Reiterated Rating||Hold||$290.00||Low|
|8/16/2017||Goldman Sachs Group, Inc. (The)||Upgrade||Buy -> Conviction-Buy||$338.00||Low|
|7/27/2017||Cowen and Company||Reiterated Rating||Buy||Medium|
|7/26/2017||Deutsche Bank AG||Reiterated Rating||Buy||$315.00 -> $319.00||Low|
|7/26/2017||Leerink Swann||Reiterated Rating||Market Perform||$304.00 -> $338.00||High|
|7/14/2017||Credit Suisse Group||Set Price Target||Hold||$300.00||Low|
|7/11/2017||Jefferies Group LLC||Reiterated Rating||Hold -> Hold||$310.00||Low|
|6/26/2017||William Blair||Reiterated Rating||Outperform||High|
|5/25/2017||Sanford C. Bernstein||Reiterated Rating||Outperform||Low|
|5/25/2017||Cantor Fitzgerald||Reiterated Rating||Hold||$277.00||Low|
|5/15/2017||Piper Jaffray Companies||Set Price Target||Buy||$332.00 -> $442.00||Low|
|4/23/2017||Barclays PLC||Reiterated Rating||Overweight||$380.00 -> $360.00||Medium|
|4/4/2017||Citigroup Inc.||Boost Price Target||Buy||$305.00 -> $315.00||Low|
|3/1/2017||Instinet||Initiated Coverage||Buy -> Buy||$223.03 -> $345.00||N/A|
|1/30/2017||HC Wainwright||Reiterated Rating||Buy||$360.00||N/A|
|1/18/2017||J P Morgan Chase & Co||Reiterated Rating||Buy||N/A|
|8/2/2016||Standpoint Research||Downgrade||Buy -> Hold||N/A|
|6/8/2016||Wells Fargo & Company||Reiterated Rating||Buy||N/A|
|12/18/2015||Atlantic Securities||Initiated Coverage||Overweight||$344.00||N/A|
Earnings History for Biogen (NASDAQ:BIIB)Earnings History by Quarter for Biogen (NASDAQ BIIB)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/25/2017||Q2 2017||$4.36||$5.04||$2.81 billion||$3.08 billion||View||N/A|
|4/25/2017||Q1 2017||$4.97||$5.20||$2.73 billion||$2.81 billion||View||N/A|
|1/26/2017||Q416||$4.96||$5.04||$2.94 billion||$2.87 billion||View||N/A|
|10/26/2016||Q316||$4.97||$5.19||$2.91 billion||$2.96 billion||View||Listen|
|7/21/2016||Q216||$4.69||$5.21||$2.79 billion||$2.89 billion||View||Listen|
|4/21/2016||Q116||$4.47||$4.79||$2.75 billion||$2.73 billion||View||Listen|
|1/27/2016||Q415||$4.08||$4.50||$2.70 billion||$2.84 billion||View||Listen|
|10/21/2015||Q315||$3.80||$4.48||$2.65 billion||$2.39 billion||View||Listen|
|7/24/2015||Q215||$4.10||$4.22||$2.71 billion||$2.59 billion||View||Listen|
|4/24/2015||Q115||$3.91||$3.82||$2.66 billion||$2.56 billion||View||Listen|
|1/29/2015||Q414||$3.74||$4.09||$2.64 billion||$2.60 billion||View||Listen|
|10/22/2014||Q3||$3.22||$3.80||$2.48 billion||$2.50 billion||View||Listen|
|7/23/2014||Q214||$2.80||$3.49||$2.14 billion||$2.42 billion||View||Listen|
|4/23/2014||Q114||$2.56||$2.47||$2.00 billion||$2.10 billion||View||Listen|
|1/29/2014||Q413||$2.27||$2.34||$1.93 billion||$2.00 billion||View||Listen|
|10/28/2013||Q313||$2.10||$2.35||$1.78 billion||$1.83 billion||View||Listen|
|7/25/2013||Q2 2013||$1.93||$2.30||$1.62 billion||$1.70 billion||View||Listen|
|4/25/2013||Q1 2013||$1.63||$1.97||$1.41 billion||$1.40 billion||View||Listen|
|1/28/2013||Q4 2012||$1.46||$1.40||$1.38 billion||$1.40 billion||View||Listen|
Earnings Estimates for Biogen (NASDAQ:BIIB)
2017 EPS Consensus Estimate: $20.39
2018 EPS Consensus Estimate: $24.24
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Biogen (NASDAQ:BIIB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Biogen (NASDAQ:BIIB)
Insider Ownership Percentage: 0.25%Insider Trades by Quarter for Biogen (NASDAQ:BIIB)
Institutional Ownership Percentage: 87.62%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/25/2017||Susan H Alexander||EVP||Sell||4,974||$290.01||$1,442,509.74|| |
|7/19/2017||Susan H Alexander||EVP||Sell||7,758||$285.00||$2,211,030.00|| |
|6/9/2017||Brian S Posner||Director||Sell||1,084||$256.31||$277,840.04|| |
|5/1/2017||Michel Vounatsos||CEO||Buy||1,402||$271.35||$380,432.70|| |
|4/27/2017||Alexander J. Denner||Director||Buy||73,858||$278.50||$20,569,453.00|| |
|4/25/2017||Paul J Clancy||VP||Sell||9,892||$290.00||$2,868,680.00|| |
|4/3/2017||Alfred Sandrock||CMO||Sell||1,981||$274.08||$542,952.48|| |
|3/13/2017||Paul J Clancy||VP||Sell||9,891||$291.55||$2,883,721.05|| |
|2/27/2017||Michel Vounatsos||CEO||Buy||1,333||$285.39||$380,424.87|| |
|1/9/2017||Robert W Pangia||Director||Sell||5,450||$295.39||$1,609,875.50|| |
|10/4/2016||Adriana Karaboutis||EVP||Sell||262||$311.94||$81,728.28|| |
|10/3/2016||Adriana Karaboutis||EVP||Sell||380||$313.00||$118,940.00|| |
|9/22/2016||Caroline Dorsa||Director||Sell||27,570||$314.00||$8,656,980.00|| |
|7/21/2016||George A Scangos||CEO||Sell||157||$280.00||$43,960.00|| |
|6/6/2016||Adam Koppel||EVP||Sell||555||$290.00||$160,950.00|| |
|6/3/2016||George A Scangos||CEO||Sell||842||$290.00||$244,180.00|| |
|6/1/2016||George A Scangos||CEO||Sell||3,855||$289.74||$1,116,947.70|| |
|5/25/2016||George A Scangos||CEO||Sell||157||$280.00||$43,960.00|| |
|5/2/2016||George A Scangos||CEO||Sell||487||$274.74||$133,798.38|| |
|4/6/2016||Adam Koppel||EVP||Sell||102||$275.00||$28,050.00|| |
|4/6/2016||George A Scangos||CEO||Sell||157||$280.00||$43,960.00|| |
|4/1/2016||George A Scangos||CEO||Sell||487||$258.83||$126,050.21|| |
|3/1/2016||George A Scangos||CEO||Sell||487||$261.37||$127,287.19|| |
|2/25/2016||Adriana Karaboutis||EVP||Sell||84||$261.90||$21,999.60|| |
|2/25/2016||Alfred Sandrock||CMO||Sell||183||$261.90||$47,927.70|| |
|2/17/2016||Alfred Sandrock||Chief Medical Officer||Sell||722||$256.16||$184,947.52|| |
|2/17/2016||George A Scangos||CEO||Sell||487||$256.16||$124,749.92|| |
|2/9/2016||Alfred Sandrock||Chief Medical Officer||Sell||852||$246.54||$210,052.08|| |
|12/4/2015||Alfred Sandrock||CMO||Sell||441||$277.00||$122,157.00|| |
|10/23/2015||Alexander J Denner||Director||Buy||310,000||$277.47||$86,015,700.00|| |
|7/27/2015||Stelios Papadopoulos||Director||Buy||10,000||$304.88||$3,048,800.00|| |
|6/19/2015||Douglas E Williams||EVP||Sell||3,841||$410.00||$1,574,810.00|| |
|6/1/2015||George A Scangos||CEO||Sell||1,362||$398.87||$543,260.94|| |
|4/1/2015||George A Scangos||CEO||Sell||1,362||$423.20||$576,398.40|| |
|3/25/2015||John Cox||EVP||Sell||12,010||$449.06||$5,393,210.60|| |
|3/20/2015||Eric K Rowinsky||Director||Sell||11,667||$475.00||$5,541,825.00|| |
|3/19/2015||Eric K Rowinsky||Director||Sell||2,333||$436.14||$1,017,514.62|| |
|3/17/2015||Eric K Rowinsky||Director||Sell||4,667||$425.45||$1,985,575.15|| |
|3/10/2015||Robert W Pangia||Director||Sell||3,625||$413.40||$1,498,575.00|| |
|3/2/2015||Alfred Sandrock||SVP||Sell||3,174||$409.49||$1,299,721.26|| |
|2/17/2015||Steven H Holtzman||EVP||Sell||2,128||$389.11||$828,026.08|| |
|2/10/2015||Alfred Sandrock||SVP||Sell||1,143||$398.11||$455,039.73|| |
|2/2/2015||Kenneth Dipietro||EVP||Sell||1,656||$389.03||$644,233.68|| |
|12/15/2014||Spyridon Artavanis-Tsakonas||SVP||Sell||1,981||$346.50||$686,416.50|| |
|12/2/2014||Steven H Holtzman||EVP||Sell||1,749||$335.65||$587,051.85|| |
|11/11/2014||Steven H Holtzman||EVP||Sell||1,750||$330.00||$577,500.00|| |
|11/3/2014||George A Scangos||CEO||Sell||1,128||$320.78||$361,839.84|| |
|10/1/2014||George A Scangos||CEO||Sell||1,127||$330.97||$373,003.19|| |
|10/1/2014||Steven H Holtzman||EVP||Sell||1,750||$330.97||$579,197.50|| |
|8/1/2014||George A Scangos||CEO||Sell||1,128||$332.93||$375,545.04|| |
|7/16/2014||George A Scangos||CEO||Sell||12,316||$312.37||$3,847,148.92|| |
|5/19/2014||Steven Holtzman||EVP||Sell||1,221||$289.15||$353,052.15|| |
|5/1/2014||George Scangos||CEO||Sell||2,123||$285.56||$606,243.88|| |
|4/17/2014||Steven Holtzman||EVP||Sell||1,221||$291.00||$355,311.00|| |
|4/1/2014||George Scangos||CEO||Sell||2,123||$308.42||$654,775.66|| |
|4/1/2014||Robert Pangia||Director||Sell||6,250||$308.42||$1,927,625.00|| |
|3/31/2014||Brian Posner||Director||Sell||3,000||$296.76||$890,280.00|| |
|3/20/2014||Caroline Dorsa||Director||Sell||10,000||$348.88||$3,488,800.00|| |
|3/19/2014||Douglas Williams||EVP||Sell||3,505||$352.29||$1,234,776.45|| |
|3/17/2014||Steven Holtzman||EVP||Sell||1,221||$334.83||$408,827.43|| |
|3/11/2014||Stuart Kingsley||EVP||Sell||8,428||$336.83||$2,838,803.24|| |
|3/3/2014||George Scangos||CEO||Sell||2,942||$335.79||$987,894.18|| |
|2/26/2014||Alfred Sandrock||SVP||Sell||1,048||$342.17||$358,594.16|| |
|2/18/2014||Steven Holtzman||EVP||Sell||1,222||$327.90||$400,693.80|| |
|2/13/2014||Kenneth Dipietro||EVP||Sell||1,290||$316.81||$408,684.90|| |
|2/11/2014||Alfred Sandrock||SVP||Sell||2,085||$314.31||$655,336.35|| |
|2/11/2014||George Scangos||CEO||Sell||2,456||$314.31||$771,945.36|| |
|2/4/2014||Kenneth Dipietro||EVP||Sell||1,655||$299.01||$494,861.55|| |
|1/21/2014||Eric Rowinsky||Director||Sell||2,020||$310.09||$626,381.80|| |
|1/15/2014||Lynn Schenk||Director||Sell||1,000||$297.48||$297,480.00|| |
|1/8/2014||William Young||Director||Sell||15,000||$285.11||$4,276,650.00|| |
|1/6/2014||Robert Pangia||Director||Sell||6,250||$278.03||$1,737,687.50|| |
|12/2/2013||Lynn Schenk||Director||Sell||1,000||$291.71||$291,710.00|| |
|11/22/2013||Raymond Pawlicki||SVP||Sell||4,000||$288.00||$1,152,000.00|| |
|11/1/2013||George A Scangos||CEO||Sell||2,239||$245.57||$549,831.23|| |
|11/1/2013||Lynn Schenk||Director||Sell||1,000||$245.00||$245,000.00|| |
|10/22/2013||Alfred Sandrock||SVP||Sell||15,030||$250.11||$3,759,153.30|| |
|9/18/2013||Paul Clancy||CFO||Sell||26,785||$245.00||$6,562,325.00|| |
|9/17/2013||Steven Holtzman||EVP||Sell||3,501||$238.98||$836,668.98|| |
|9/16/2013||Paul Clancy||CFO||Sell||99,030||$238.27||$23,595,878.10|| |
|9/16/2013||Raymond Pawlicki||SVP||Sell||4,000||$238.03||$952,120.00|| |
|9/3/2013||George Scangos||CEO||Sell||2,239||$214.40||$480,041.60|| |
|8/26/2013||Douglas Williams||EVP||Sell||4,368||$211.35||$923,176.80|| |
|8/1/2013||George A Scangos||CEO||Sell||2,239||$218.82||$489,937.98|| |
|7/16/2013||George A Scangos||CEO||Sell||2,239||$223.94||$501,401.66|| |
|6/14/2013||Alexander J Denner||Director||Sell||2,900||$212.00||$614,800.00|| |
|6/11/2013||Brian S Posner||Director||Sell||2,020||$219.62||$443,632.40|| |
|6/10/2013||Lynn Schenk||Director||Sell||2,000||$225.82||$451,640.00|| |
|6/3/2013||George A Scangos||CEO||Sell||1,598||$234.16||$374,187.68|| |
|6/3/2013||Stephen A Sherwin||Director||Sell||12,825||$233.26||$2,991,559.50|| |
|5/28/2013||Robert W Pangia||Director||Sell||5,900||$237.23||$1,399,657.00|| |
|12/27/2012||Alexander J Denner||Director||Sell||7,980||$148.62||$1,185,987.60|| |
Headline Trends for Biogen (NASDAQ:BIIB)
Latest Headlines for Biogen (NASDAQ:BIIB)
Loading headlines, please wait.
Biogen (BIIB) Chart for Sunday, October, 22, 2017